51
|
Abstract
Autophagy is a catabolic program that is responsible for the degradation of dysfunctional or unnecessary proteins and organelles to maintain cellular homeostasis. Mechanistically, it involves the formation of double-membrane autophagosomes that sequester cytoplasmic material and deliver it to lysosomes for degradation. Eventually, the material is recycled back to the cytoplasm. Abnormalities of autophagy often lead to human diseases, such as neurodegeneration and cancer. In the case of cancer, increasing evidence has revealed the paradoxical roles of autophagy in both tumor inhibition and tumor promotion. Here, we summarize the context-dependent role of autophagy and its complicated molecular mechanisms in the hallmarks of cancer. Moreover, we discuss how therapeutics targeting autophagy can counter malignant transformation and tumor progression. Overall, the findings of studies discussed here shed new light on exploiting the complicated mechanisms of the autophagic machinery and relevant small-molecule modulators as potential antitumor agents to improve therapeutic outcomes.
Collapse
Affiliation(s)
- Tianzhi Huang
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Xiao Song
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Yongyong Yang
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Xuechao Wan
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Angel A. Alvarez
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Namratha Sastry
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Haizhong Feng
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Bo Hu
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| | - Shi-Yuan Cheng
- Ken & Ruth Davee Department of Neurology, Lou & Jean Malnati Brain Tumor Institute, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
| |
Collapse
|
52
|
Huang T, Kim CK, Alvarez AA, Pangeni RP, Wan X, Song X, Shi T, Yang Y, Sastry N, Horbinski CM, Lu S, Stupp R, Kessler JA, Nishikawa R, Nakano I, Sulman EP, Lu X, James CD, Yin XM, Hu B, Cheng SY. MST4 Phosphorylation of ATG4B Regulates Autophagic Activity, Tumorigenicity, and Radioresistance in Glioblastoma. Cancer Cell 2017; 32:840-855.e8. [PMID: 29232556 PMCID: PMC5734934 DOI: 10.1016/j.ccell.2017.11.005] [Citation(s) in RCA: 166] [Impact Index Per Article: 23.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Revised: 09/11/2017] [Accepted: 11/07/2017] [Indexed: 02/05/2023]
Abstract
ATG4B stimulates autophagy by promoting autophagosome formation through reversible modification of ATG8. We identify ATG4B as a substrate of mammalian sterile20-like kinase (STK) 26/MST4. MST4 phosphorylates ATG4B at serine residue 383, which stimulates ATG4B activity and increases autophagic flux. Inhibition of MST4 or ATG4B activities using genetic approaches or an inhibitor of ATG4B suppresses autophagy and the tumorigenicity of glioblastoma (GBM) cells. Furthermore, radiation induces MST4 expression, ATG4B phosphorylation, and autophagy. Inhibiting ATG4B in combination with radiotherapy in treating mice with intracranial GBM xenograft markedly slows tumor growth and provides a significant survival benefit. Our work describes an MST4-ATG4B signaling axis that influences GBM autophagy and malignancy, and whose therapeutic targeting enhances the anti-tumor effects of radiotherapy.
Collapse
Affiliation(s)
- Tianzhi Huang
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Chung Kwon Kim
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Angel A Alvarez
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Rajendra P Pangeni
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Xuechao Wan
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Xiao Song
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Taiping Shi
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Yongyong Yang
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Namratha Sastry
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Craig M Horbinski
- The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Songjian Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA
| | - Roger Stupp
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - John A Kessler
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Ryo Nishikawa
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
| | - Ichiro Nakano
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA
| | - Xinghua Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA 15206, USA
| | - Charles David James
- The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Xiao-Ming Yin
- Department of Pathology & Laboratory Medicine, Indiana University, Indianapolis, IN 46202, USA
| | - Bo Hu
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
| | - Shi-Yuan Cheng
- Ken & Ruth Davee Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; The Lou and Jean Malnati Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
| |
Collapse
|
53
|
Lv D, Li Y, Zhang W, Alvarez AA, Song L, Tang J, Gao WQ, Hu B, Cheng SY, Feng H. TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma. Nat Commun 2017; 8:1454. [PMID: 29129908 PMCID: PMC5682287 DOI: 10.1038/s41467-017-01731-w] [Citation(s) in RCA: 95] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2017] [Accepted: 10/12/2017] [Indexed: 12/17/2022] Open
Abstract
Aberrant amplification and mutations of epidermal growth factor receptor (EGFR) are the most common oncogenic events in glioblastoma (GBM), but the mechanisms by which they promote aggressive pathogenesis are not well understood. Here, we determine that non-canonical histone signature acetylated H3 lysine 23 (H3K23ac)-binding protein tripartite motif-containing 24 (TRIM24) is upregulated in clinical GBM specimens and required for EGFR-driven tumorigenesis. In multiple glioma cell lines and patient-derived glioma stem cells (GSCs), EGFR signaling promotes H3K23 acetylation and association with TRIM24. Consequently, TRIM24 functions as a transcriptional co-activator and recruits STAT3, leading to stabilized STAT3-chromatin interactions and subsequent activation of STAT3 downstream signaling, thereby enhancing EGFR-driven tumorigenesis. Our findings uncover a pathway in which TRIM24 functions as a signal relay for oncogenic EGFR signaling and suggest TRIM24 as a potential therapeutic target for GBM that are associated with EGFR activation. EGF receptor (EGFR) amplification and mutation are major drivers in glioma tumorigenesis but this mechanism is not well understood. Here, the authors show EGFR-upregulated H3K23ac binds TRIM24 which recruits STAT3, leading to activation of STAT3 signaling, enhancing EGFR-driven tumorigenesis.
Collapse
Affiliation(s)
- Deguan Lv
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.,School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 310000, China
| | - Yanxin Li
- Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China
| | - Weiwei Zhang
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China
| | - Angel A Alvarez
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA
| | - Lina Song
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China
| | - Jianming Tang
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China
| | - Wei-Qiang Gao
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China
| | - Bo Hu
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA
| | - Shi-Yuan Cheng
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.,Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA
| | - Haizhong Feng
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
| |
Collapse
|
54
|
Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC. Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. Mol Cancer Res 2017; 16:32-46. [PMID: 29042487 DOI: 10.1158/1541-7786.mcr-17-0397] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2017] [Revised: 09/13/2017] [Accepted: 10/11/2017] [Indexed: 12/16/2022]
Abstract
Mesenchymal (MES) and proneural (PN) are two distinct glioma stem cell (GSC) populations that drive therapeutic resistance in glioblastoma (GBM). We screened a panel of 650 small molecules against patient-derived GBM cells to discover compounds targeting specific GBM subtypes. Arsenic trioxide (ATO), an FDA-approved drug that crosses the blood-brain barrier, was identified as a potent PN-specific compound in the initial screen and follow-up validation studies. Furthermore, MES and PN GSCs exhibited differential sensitivity to ATO. As ATO has been shown to activate the MAPK-interacting kinase 1 (MNK1)-eukaryotic translation initiation factor 4E (eIF4E) pathway and subsequent mRNA translation in a negative regulatory feedback manner, the mechanistic role of ATO resistance in MES GBM was explored. In GBM cells, ATO-activated translation initiation cellular events via the MNK1-eIF4E signaling axis. Furthermore, resistance to ATO in intracranial PDX tumors correlated with high eIF4E phosphorylation. Polysomal fractionation and microarray analysis of GBM cells were performed to identify ATO's effect on mRNA translation and enrichment of anti-apoptotic mRNAs in the ATO-induced translatome was found. Additionally, it was determined that MNK inhibition sensitized MES GSCs to ATO in neurosphere and apoptosis assays. Finally, examination of the effect of ATO on patients from a phase I/II clinical trial of ATO revealed that PN GBM patients responded better to ATO than other subtypes as demonstrated by longer overall and progression-free survival.Implications: These findings raise the possibility of a unique therapeutic approach for GBM, involving MNK1 targeting to sensitize MES GSCs to drugs like arsenic trioxide. Mol Cancer Res; 16(1); 32-46. ©2017 AACR.
Collapse
Affiliation(s)
- Jonathan B Bell
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Frank Eckerdt
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Harshil D Dhruv
- Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona
| | - Darren Finlay
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California
| | - Sen Peng
- Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona
| | - Seungchan Kim
- Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona.,Department of Electrical and Computer Engineering, Roy G. Perry College of Engineering, Prairie View A&M University, Prairie View, Texas
| | - Barbara Kroczynska
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Elspeth M Beauchamp
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois
| | - Kristen Alley
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jessica Clymer
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Stewart Goldman
- Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Shi-Yuan Cheng
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - C David James
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Ichiro Nakano
- Department of Neurosurgery and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Craig Horbinski
- Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Andrew P Mazar
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Developmental Therapeutics Core, Center for Developmental Therapeutics, Northwestern University, Evanston, Illinois
| | - Kristiina Vuori
- Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California
| | - Priya Kumthekar
- Division of Neuro-Oncology, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jeffrey Raizer
- Division of Neuro-Oncology, Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Michael E Berens
- Cancer and Cell Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona
| | - Leonidas C Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. .,Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.,Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois
| |
Collapse
|
55
|
Lv D, Jia F, Hou Y, Sang Y, Alvarez AA, Zhang W, Gao WQ, Hu B, Cheng SY, Ge J, Li Y, Feng H. Histone Acetyltransferase KAT6A Upregulates PI3K/AKT Signaling through TRIM24 Binding. Cancer Res 2017; 77:6190-6201. [PMID: 29021135 DOI: 10.1158/0008-5472.can-17-1388] [Citation(s) in RCA: 60] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2017] [Revised: 08/28/2017] [Accepted: 10/03/2017] [Indexed: 12/31/2022]
Abstract
Lysine acetyltransferase KAT6A is a chromatin regulator that contributes to histone modification and cancer, but the basis of its actions are not well understood. Here, we identify a KAT6A signaling pathway that facilitates glioblastoma (GBM), where it is upregulated. KAT6A expression was associated with GBM patient survival. KAT6A silencing suppressed cell proliferation, cell migration, colony formation, and tumor development in an orthotopic mouse xenograft model system. Mechanistic investigations demonstrated that KAT6A acetylates lysine 23 of histone H3 (H3K23), which recruits the nuclear receptor binding protein TRIM24 to activate PIK3CA transcription, thereby enhancing PI3K/AKT signaling and tumorigenesis. Overexpressing activated AKT or PIK3CA rescued the growth inhibition due to KAT6A silencing. Conversely, the pan-PI3K inhibitor LY294002 abrogated the growth-promoting effect of KAT6A. Overexpression of KAT6A or TRIM24, but not KAT6A acetyltransferase activity-deficient mutants or TRIM24 mutants lacking H3K23ac-binding sites, promoted PIK3CA expression, AKT phosphorylation, and cell proliferation. Taken together, our results define an essential role of KAT6A in glioma formation, rationalizing its candidacy as a therapeutic target for GBM treatment. Cancer Res; 77(22); 6190-201. ©2017 AACR.
Collapse
Affiliation(s)
- Deguan Lv
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China.,Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China
| | - Feng Jia
- Department of Neurosurgery, Ren Ji Hospital, Shanghai, China
| | - Yanli Hou
- Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
| | - Youzhou Sang
- Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China
| | - Angel A Alvarez
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Weiwei Zhang
- Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China
| | - Wei-Qiang Gao
- Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China
| | - Bo Hu
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Shi-Yuan Cheng
- Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China.,Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | - Jianwei Ge
- Department of Neurosurgery, Ren Ji Hospital, Shanghai, China.
| | - Yanxin Li
- Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
| | - Haizhong Feng
- Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai, China.
| |
Collapse
|
56
|
Hua YZ, Cheng SY, Jiang GH, Zhao MW. [Clinical value of T-cell interferon releases detection of tuberculosis infection assay in quick diagnosis of spinal tuberculosis]. Zhonghua Yi Xue Za Zhi 2017; 96:2179-81. [PMID: 27464546 DOI: 10.3760/cma.j.issn.0376-2491.2016.27.015] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
OBJECTIVE To evaluate the value of T-cell interferon releases detection of tuberculosis infection(T-SPOT.TB)assay in quick diagnosis of spinal tuberculosis. METHODS From January 2012 to June 2015, a group of 122 diagnosed patients with spinal tuberculosis in the Qingdao Municipal Chest Hospital and a group of 86 patients suspected with spinal tuberculosis in Department of Orthopaedic, the Qingdao Third People's Hospital were accepted to undergone TB-DOT, T-SPOT.TB and TB-DNA PCR tests Department of Clinical Laboratory. RESULTS The sensitivity of TB-DOT, T-SPOT.TB and TB-DNA PCR tests were 69.7%, 86.1% and 56.6%, respectively.The sensitivity of T-SPOT.TB was significantly higher than TB-DOT and TB-DNA PCR tests (χ(2)=9.51, P<0.05; χ(2)=25.96, P<0.05). The specificity of TB-DOT, T-SPOT.TB and TB-DNA PCR tests were 62.8%, 88.3% and 91.9%, respectively.The specificity of T-SPOT.TB was significantly higher than TB-DOT test (χ(2)=15.25, P<0.05). CONCLUSIONS T-SPOT.TB assay possesses high sensitivity and specificity in quick diagnosis of patients with spinal tuberculosis, which is valuable in diagnosis of spinal tuberculosis.
Collapse
Affiliation(s)
- Y Z Hua
- Department of Clinical Laboratory, Qingdao Municipal Chest Hospital, Qingdao 266041, China
| | | | | | | |
Collapse
|
57
|
Zhang W, Yan L, Zhang W, Tong Y, Cheng SY. The US Chinese Anti-Cancer Association and the Asian Fund for Cancer Research Recognize Young Chinese Cancer Researchers with the 2016 USCACA-AFCR scholar awards. Chin J Cancer 2017; 36:30. [PMID: 28314389 PMCID: PMC5357331 DOI: 10.1186/s40880-017-0197-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/08/2017] [Accepted: 03/08/2017] [Indexed: 12/04/2022]
Affiliation(s)
- Wei Zhang
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553 USA
- Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611 USA
| | - Li Yan
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553 USA
- Beijing Cancer Hospital and Institute, Peking University School of Oncology, Beijing, 100142 China
| | - Wei Zhang
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553 USA
- Department of Cancer Biology, Wake Forest University, Winston-Salem, NC 27157 USA
| | - Yunguang Tong
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553 USA
- Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
- University of California, Los Angeles, School of Medicine, Los Angeles, CA USA
| | - Shi-Yuan Cheng
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553 USA
- Department of Neurology, Northwestern Feinberg School of Medicine, Chicago, IL 60611 USA
| |
Collapse
|
58
|
Pangeni R, Alvarez A, Huang T, Zhang W, Zhang Z, Sastry N, Lu S, Kessler J, Brenann C, Sulman E, Lu X, Nakano I, Hu B, Cheng SY. GENT-14. GENOME WIDE METHYLOMIC AND TRANSCRIPTOMIC ANALYSES IDENTIFY EPIGENETIC SIGNATURES UNIQUELY DYSREGULATED IN GBM SUBTYPES. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
59
|
Alvarez A, Huang T, Pangeni R, Lu S, Brennan C, Sulman E, Lu X, Nakano I, Zhang W, Zhang Z, Hu B, Cheng SY. STMC-35. DIVERGENT Wnt SIGNALING REGULATES GLIOMA STEM CELLS AND TUMOR PHENOTYPE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
60
|
Huang T, Alvarez A, Pangeni R, Horbinski C, Lu S, James CD, Raizer J, Brenann C, Sulman E, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY. CSIG-08. A REGULATORY CIRCUIT OF miR-125b/miR-20b AND Wnt SIGNALING CONTROLS GBM PHENOTYPES THROUGH FZD6-MEDIATED PATHWAYS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now212.169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
61
|
Li KC, Cheng SY, Du J, Li J. [Second-line treatment for metastatic or locally advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi 2016; 38:721-724. [PMID: 27784452 DOI: 10.3760/cma.j.issn.0253-3766.2016.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Gastric cancer is one of the major causes of cancer-related deaths. Many patients with metastatic gastric cancer after first-line chemotherapy received salvage chemotherapy in routine clinical practice. Recent phase Ⅲ trials demonstrated substantial prolongation of overall survival to support this chemotherapy or targeted therapy as a second-line treatment. Both ramucirumab monotherapy and ramucirumab plus paclitaxel were approved by FDA in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma. In addition, paclitaxel, irinotecan, or docetaxel monotherapy is also recommended for preferred regimens. This review will summarize chemotherapy or targeted therapy as a second-line treatment in advanced gastric cancer.
Collapse
Affiliation(s)
- K C Li
- Departmentof Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai 200331, China
| | - S Y Cheng
- Departmentof Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai 200331, China
| | - J Du
- Departmentof Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai 200331, China
| | - J Li
- Departmentof Oncology, Tianyou Hospital Affiliated to Tongji University, Shanghai 200331, China
| |
Collapse
|
62
|
Huang T, Alvarez AA, Pangeni RP, Horbinski CM, Lu S, Kim SH, James CD, J Raizer J, A Kessler J, Brenann CW, Sulman EP, Finocchiaro G, Tan M, Nishikawa R, Lu X, Nakano I, Hu B, Cheng SY. A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nat Commun 2016; 7:12885. [PMID: 27698350 PMCID: PMC5059456 DOI: 10.1038/ncomms12885] [Citation(s) in RCA: 65] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2016] [Accepted: 08/11/2016] [Indexed: 12/16/2022] Open
Abstract
Molecularly defined subclassification is associated with phenotypic malignancy of glioblastoma (GBM). However, current understanding of the molecular basis of subclass conversion that is often involved in GBM recurrence remain rudimentary at best. Here we report that canonical Wnt signalling that is active in proneural (PN) but inactive in mesenchymal (MES) GBM, along with miR-125b and miR-20b that are expressed at high levels in PN compared with MES GBM, comprise a regulatory circuit involving TCF4-miR-125b/miR-20b-FZD6. FZD6 acts as a negative regulator of this circuit by activating CaMKII–TAK1–NLK signalling, which, in turn, attenuates Wnt pathway activity while promoting STAT3 and NF-κB signalling that are important regulators of the MES-associated phenotype. These findings are confirmed by targeting differentially enriched pathways in PN versus MES GBM that results in inhibition of distinct GBM subtypes. Correlative expressions of the components of this circuit are prognostic relevant for clinical GBM. Our findings provide insights for understanding GBM pathogenesis and for improving treatment of GBM. Glioblastoma (GBM) is classified as proneural (PN), neural, mesenchymal (MES) and classical GBM. Here the authors show that Wnt signalling, miR-125b and miR-20b establish a regulatory circuitry including FZD6 which distinguishes PN from the MES subtype.
Collapse
Affiliation(s)
- Tianzhi Huang
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Angel A Alvarez
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Rajendra P Pangeni
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Craig M Horbinski
- Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Songjian Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania 15206, USA
| | - Sung-Hak Kim
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
| | - C David James
- Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Jeffery J Raizer
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - John A Kessler
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Cameron W Brenann
- Human Oncology and Pathogenesis Program, Department of Neurosurgery, Brain Tumor Center, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
| | - Gaetano Finocchiaro
- Unit of Molecular Neuro-Oncology, Department of Neuro-Oncology, Fondazione IRCCS Istituto Neurologico, Via Celoria 11, 20133 Milano, Italy
| | - Ming Tan
- Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama 36604, USA
| | - Ryo Nishikawa
- Department of Neuro-Oncology/Neurosurgery, Saitama Medical University International Medical Center, Saitama, 350-1298, Japan
| | - Xinghua Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania 15206, USA
| | - Ichiro Nakano
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
| | - Bo Hu
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| | - Shi-Yuan Cheng
- Department of Neurology, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
| |
Collapse
|
63
|
Abstract
OBJECTIVE Costs for radiation therapy (rt) and the methods used to cost rt are highly diverse across the literature. To date, no study has compared various costing methods in detail. Our objective was to perform a thorough review of the radiation costing literature to identify sources of costs and methods used. METHODS A systematic review of Ovid medline, Ovid oldmedline, embase, Ovid HealthStar, and EconLit from 2005 to 23 March 2015 used search terms such as "radiation," "radiotherapy," "neoplasm," "cost," " cost analysis," and "cost benefit analysis" to locate relevant articles. Original papers were reviewed for detailed costing methods. Cost sources and methods were extracted for papers investigating rt modalities, including three-dimensional conformal rt (3D-crt), intensity-modulated rt (imrt), stereotactic body rt (sbrt), and brachytherapy (bt). All costs were translated into 2014 U.S. dollars. RESULTS Most of the studies (91%) reported in the 33 articles retrieved provided rt costs from the health system perspective. The cost of rt ranged from US$2,687.87 to US$111,900.60 per treatment for imrt, followed by US$5,583.28 to US$90,055 for 3D-crt, US$10,544.22 to US$78,667.40 for bt, and US$6,520.58 to US$19,602.68 for sbrt. Cost drivers were professional or personnel costs and the cost of rt treatment. Most studies did not address the cost of rt equipment (85%) and institutional or facility costs (66%). CONCLUSIONS Costing methods and sources were widely variable across studies, highlighting the need for consistency in the reporting of rt costs. More work to promote comparability and consistency across studies is needed.
Collapse
Affiliation(s)
- F Rahman
- Institute for Clinical Evaluative Sciences, ON
| | - S J Seung
- Health Outcomes and Pharmacoeconomics ( hope ) Research Centre, Sunnybrook Research Institute, ON
| | - S Y Cheng
- Institute for Clinical Evaluative Sciences, ON
| | - H Saherawala
- Health Outcomes and Pharmacoeconomics ( hope ) Research Centre, Sunnybrook Research Institute, ON
| | - C C Earle
- Institute for Clinical Evaluative Sciences, ON
| | - N Mittmann
- Cancer Care Ontario, ON.; University of Toronto, ON.; Sunnybrook Research Institute, Toronto, ON
| |
Collapse
|
64
|
Zhang L, Zhang W, Li Y, Li Z, Wang Y, Song L, Lv D, Nakano I, Hu B, Cheng SY, Feng H. Abstract 695: SHP-2-upregulated ZEB1 is important for PDGFRá-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A critical clinical challenge in glioblastoma therapy is robust tumor growth and invasion driven by aberrant activation of oncogenic tyrosine receptor kinases (RTKs) including PDGFRá. Here, we report that a SHP-2-upregulated epithelial-mesenchymal transition (EMT)-inducer, ZEB1 is important for PDGFRá-driven glioma EMT, invasion and glioma stem cell renewal in mice and humans. ZEB1 and activated PDGFRá were co-expressed in invasive regions of mouse glioma xenografts and human clinical glioma specimens. Glioma patients with high levels of both p-PDGFRá and ZEB1 had significantly shorter overall survival compared with those with low expression of p-PDGFRá and ZEB1. Knockdown of ZEB1 inhibited PDGF-A/PDGFRá-stimulated glioma EMT, tumor growth, invasion and glioma stem cell renewal. PDGFRá mutant deficient of SHP-2 binding (PDGFRá-F720) or PI3K binding (PDGFRá-F731/42), knockdown of SHP-2 or treatments of pharmacological inhibitor for PDGFRá-signaling effectors attenuated PDGF-A/PDGFRá-stimulated ZEB1 expression, cell migration and glioma stem cell proliferation. Importantly, SHP-2 acts together with PI3K/Akt to regulate a ZEB1-miR-200 feedback loop in PDGFRá-driven gliomas. Together, our findings uncover a new pathway in which ZEB1 functions as a key regulator for PDGFRá-driven glioma EMT, invasion and glioma stem cell renewal, suggesting that ZEB1 as a potential therapeutic target for human gliomas with high PDGFRá activation.
Citation Format: Lei Zhang, Weiwei Zhang, Yanxin Li, Zuoqing Li, Yinfang Wang, Lina Song, Deguan Lv, Ichiro Nakano, Bo Hu, Shi-Yuan Cheng, Haizhong Feng. SHP-2-upregulated ZEB1 is important for PDGFRá-driven glioma epithelial-mesenchymal transition and invasion in mice and humans. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 695.
Collapse
Affiliation(s)
- Lei Zhang
- 1Shanghai Jiao Tong University, Shanghai, China
| | | | - Yanxin Li
- 1Shanghai Jiao Tong University, Shanghai, China
| | - Zuoqing Li
- 1Shanghai Jiao Tong University, Shanghai, China
| | | | - Lina Song
- 1Shanghai Jiao Tong University, Shanghai, China
| | - Deguan Lv
- 1Shanghai Jiao Tong University, Shanghai, China
| | | | - Bo Hu
- 3Northwestern University, Chicago, IL
| | | | | |
Collapse
|
65
|
Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD. Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol 2016; 18:1519-1528. [PMID: 27370397 DOI: 10.1093/neuonc/now106] [Citation(s) in RCA: 56] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Accepted: 04/20/2016] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Radiation therapy is the most commonly used postsurgical treatment for primary malignant brain tumors. Consequently, investigating the efficacy of chemotherapeutics combined with radiation for treating malignant brain tumors is of high clinical relevance. In this study, we examined the cyclin-dependent kinase 4/6 inhibitor palbociclib, when used in combination with radiation for treating human atypical teratoid rhabdoid tumor (ATRT) as well as glioblastoma (GBM). METHODS Evaluation of treatment antitumor activity in vitro was based upon results from cell proliferation assays, clonogenicity assays, flow cytometry, and immunocytochemistry for DNA double-strand break repair. Interpretation of treatment antitumor activity in vivo was based upon bioluminescence imaging, animal subject survival analysis, and staining of tumor sections for markers of proliferation and apoptosis. RESULTS For each of the retinoblastoma protein (RB)-proficient tumor models examined (2 ATRTs and 2 GBMs), one or more of the combination therapy regimens significantly (P < .05) outperformed both monotherapies with respect to animal subject survival benefit. Among the combination therapy regimens, concurrent palbociclib and radiation treatment and palbociclib treatment following radiation consistently outperformed the sequence in which radiation followed palbociclib treatment. In vitro investigation revealed that the concurrent use of palbociclib with radiation, as well as palbociclib following radiation, inhibited DNA double-strand break repair and promoted increased tumor cell apoptosis. CONCLUSIONS Our results support further investigation and possible clinical translation of palbociclib as an adjuvant to radiation therapy for patients with malignant brain tumors that retain RB expression.
Collapse
Affiliation(s)
- Rintaro Hashizume
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Ali Zhang
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Sabine Mueller
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Michael D Prados
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Rishi R Lulla
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Stewart Goldman
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Amanda M Saratsis
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Andrew P Mazar
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Alexander H Stegh
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Shi-Yuan Cheng
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Craig Horbinski
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Daphne A Haas-Kogan
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Jann N Sarkaria
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - Todd Waldman
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| | - C David James
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., A.Z., C.D.J., A.M.S., C.H.); Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., C.D.J.); Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (A.H.S., S.-Y.C.), Northwestern Brain Tumor Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.M.S., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois (R.H., R.R.L., S.G., A.P.M., A.H.S., S.-Y.C., C.H., C.D.J.); Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois (A.P.M., C.D.J.); Department of Pediatrics, Division of Hematology/Oncology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois (R.R.L., S.G.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (S.M., M.D.P.); Department of Pediatrics, University of California San Francisco, San Francisco, California (S.M.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (D.A.H.-K.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Lombardi Cancer Center, Georgetown University, Washington, DC (T.W.)
| |
Collapse
|
66
|
Bell JB, Eckerdt FD, Alley K, Magnusson LP, Hussain H, Bi Y, Arslan AD, Clymer J, Alvarez AA, Goldman S, Cheng SY, Nakano I, Horbinski C, Davuluri RV, James CD, Platanias LC. MNK Inhibition Disrupts Mesenchymal Glioma Stem Cells and Prolongs Survival in a Mouse Model of Glioblastoma. Mol Cancer Res 2016; 14:984-993. [PMID: 27364770 DOI: 10.1158/1541-7786.mcr-16-0172] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Accepted: 06/11/2016] [Indexed: 12/18/2022]
Abstract
Glioblastoma multiforme remains the deadliest malignant brain tumor, with glioma stem cells (GSC) contributing to treatment resistance and tumor recurrence. We have identified MAPK-interacting kinases (MNK) as potential targets for the GSC population in glioblastoma multiforme. Isoform-level subtyping using The Cancer Genome Atlas revealed that both MNK genes (MKNK1 and MKNK2) are upregulated in mesenchymal glioblastoma multiforme as compared with other subtypes. Expression of MKNK1 is associated with increased glioma grade and correlated with the mesenchymal GSC marker, CD44, and coexpression of MKNK1 and CD44 predicts poor survival in glioblastoma multiforme. In established and patient-derived cell lines, pharmacologic MNK inhibition using LY2801653 (merestinib) inhibited phosphorylation of the eukaryotic translation initiation factor 4E, a crucial effector for MNK-induced mRNA translation in cancer cells and a marker of transformation. Importantly, merestinib inhibited growth of GSCs grown as neurospheres as determined by extreme limiting dilution analysis. When the effects of merestinib were assessed in vivo using an intracranial xenograft mouse model, improved overall survival was observed in merestinib-treated mice. Taken together, these data provide strong preclinical evidence that pharmacologic MNK inhibition targets mesenchymal glioblastoma multiforme and its GSC population. IMPLICATIONS These findings raise the possibility of MNK inhibition as a viable therapeutic approach to target the mesenchymal subtype of glioblastoma multiforme. Mol Cancer Res; 14(10); 984-93. ©2016 AACR.
Collapse
Affiliation(s)
- Jonathan B Bell
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Frank D Eckerdt
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Kristen Alley
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Lisa P Magnusson
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Hridi Hussain
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Yingtao Bi
- Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Ahmet Dirim Arslan
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jessica Clymer
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Angel A Alvarez
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Stewart Goldman
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Division of Hematology/Oncology/Stem Cell Transplantation, Department of Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
| | - Shi-Yuan Cheng
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Ichiro Nakano
- Department of Neurosurgery and Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama
| | - Craig Horbinski
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Ramana V Davuluri
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - C David James
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Leonidas C Platanias
- Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Department of Medicine, Jesse Brown VA Medical Center, Chicago, Illinois.
| |
Collapse
|
67
|
Zhang H, Lin Y, Li K, Liang J, Xiao X, Cai J, Tan Y, Xing F, Mai J, Li Y, Chen W, Sheng L, Gu J, Zhu W, Yin W, Qiu P, Su X, Lu B, Tian X, Liu J, Lu W, Dou Y, Huang Y, Hu B, Kang Z, Gao G, Mao Z, Cheng SY, Lu L, Bai XT, Gong S, Yan G, Hu J. Naturally Existing Oncolytic Virus M1 Is Nonpathogenic for the Nonhuman Primates After Multiple Rounds of Repeated Intravenous Injections. Hum Gene Ther 2016; 27:700-11. [PMID: 27296553 DOI: 10.1089/hum.2016.038] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Cancers figure among the leading causes of morbidity and mortality worldwide. The number of new cases is expected to rise by about 70% over the next 2 decades. Development of novel therapeutic agents is urgently needed for clinical cancer therapy. Alphavirus M1 is a Getah-like virus isolated from China with a genome of positive single-strand RNA. We have previously identified that alphavirus M1 is a naturally existing oncolytic virus with significant anticancer activity against different kinds of cancer (e.g., liver cancer, bladder cancer, and colon cancer). To support the incoming clinical trial of intravenous administration of alphavirus M1 to cancer patients, we assessed the safety of M1 in adult nonhuman primates. We previously presented the genome sequencing data of the cynomolgus macaques (Macaca fascicularis), which was demonstrated as an ideal animal species for virus infection study. Therefore, we chose cynomolgus macaques of either sex for the present safety study of oncolytic virus M1. In the first round of administration, five experimental macaques were intravenously injected with six times of oncolytic virus M1 (1 × 10(9) pfu/dose) in 1 week, compared with five vehicle-injected control animals. The last two rounds of injections were further completed in the following months in the same way as the first round. Body weight, temperature, complete blood count, clinical biochemistries, cytokine profiles, lymphocytes subsets, neutralizing antibody, and clinical symptoms were closely monitored at different time points. Magnetic resonance imaging was also performed to assess the possibility of encephalitis or arthritis. As a result, no clinical, biochemical, immunological, or medical imaging or other pathological evidence of toxicity was found during the whole process of the study. Our results in cynomolgus macaques suggested the safety of intravenous administration of oncolytic virus M1 in cancer patients in the future.
Collapse
Affiliation(s)
- Haipeng Zhang
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China.,2 Department of Nutrition, School of Public Health, Sun Yat-sen University , Guangzhou, China
| | - Yuan Lin
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China.,3 Department of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University , Guangzhou, China
| | - Kai Li
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Jiankai Liang
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Xiao Xiao
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Jing Cai
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Yaqian Tan
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Fan Xing
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Jialuo Mai
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Yuan Li
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Wenli Chen
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Longxiang Sheng
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Jiayu Gu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Wenbo Zhu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Wei Yin
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China.,4 Department of Biochemistry, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Pengxin Qiu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Xingwen Su
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Bingzheng Lu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Xuyan Tian
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Jinhui Liu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Wanjun Lu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Yunling Dou
- 5 Department of Anesthesiology, The First Affiliated Hospital of Sun Yat-sen University , Guangzhou, China
| | - Yijun Huang
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| | - Bing Hu
- 6 Diagnostic Imaging Department, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China
| | - Zhuang Kang
- 6 Diagnostic Imaging Department, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China
| | - Guangping Gao
- 7 Horae Gene Therapy Center, Department of Microbiology and Physiology Systems, University of Massachusetts Medical School , Worcester, Massachusetts
| | - Zixu Mao
- 8 Department of Pharmacology and Neurology, Emory University School of Medicine , Atlanta, Georgia
| | - Shi-Yuan Cheng
- 9 Department of Neurology & Northwestern Brain Tumor Institute, Center for Genetic Medicine, H. Robert Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine , Chicago, Illinois
| | - Ling Lu
- 10 The Laboratory for Hepatology Research, The Third Affiliated Hospital of Sun Yat-sen University , Guangzhou, China.,11 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center , Kansas City, Kansas
| | - Xue-Tao Bai
- 11 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center , Kansas City, Kansas
| | - Shoufang Gong
- 7 Horae Gene Therapy Center, Department of Microbiology and Physiology Systems, University of Massachusetts Medical School , Worcester, Massachusetts
| | - Guangmei Yan
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China.,12 Sun Yat-sen University Cancer Center , Collaborative Innovation Center for Cancer Medicine, Guangzhou, China
| | - Jun Hu
- 1 Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China.,13 Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University , Guangzhou, China
| |
Collapse
|
68
|
Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, Ladner K, Furuta T, Sabit H, Chhipa R, Cho JH, Mohyeldin A, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng SY, Lee LJ, Nakada M, Guttridge D, DasGupta B, Goidts V, Bhat KP, Nakano I. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell 2016; 29:201-13. [PMID: 26859459 PMCID: PMC4837946 DOI: 10.1016/j.ccell.2016.01.005] [Citation(s) in RCA: 115] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 06/26/2015] [Accepted: 01/11/2016] [Indexed: 12/24/2022]
Abstract
Activation of nuclear factor κB (NF-κB) induces mesenchymal (MES) transdifferentiation and radioresistance in glioma stem cells (GSCs), but molecular mechanisms for NF-κB activation in GSCs are currently unknown. Here, we report that mixed lineage kinase 4 (MLK4) is overexpressed in MES but not proneural (PN) GSCs. Silencing MLK4 suppresses self-renewal, motility, tumorigenesis, and radioresistance of MES GSCs via a loss of the MES signature. MLK4 binds and phosphorylates the NF-κB regulator IKKα, leading to activation of NF-κB signaling in GSCs. MLK4 expression is inversely correlated with patient prognosis in MES, but not PN high-grade gliomas. Collectively, our results uncover MLK4 as an upstream regulator of NF-κB signaling and a potential molecular target for the MES subtype of glioblastomas.
Collapse
Affiliation(s)
- Sung-Hak Kim
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA
| | - Ravesanker Ezhilarasan
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Emma Phillips
- Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany
| | - Daniel Gallego-Perez
- Department of Surgery, The Ohio State University, Columbus, OH 43210, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH 43210, USA; Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, Columbus, OH 43210, USA; Center for Regenerative Medicine and Cell-Based Therapies, The Ohio State University, Columbus, OH 43210, USA
| | - Amanda Sparks
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - David Taylor
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Katherine Ladner
- Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
| | - Takuya Furuta
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Hemragul Sabit
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Rishi Chhipa
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45242, USA
| | - Ju Hwan Cho
- Department of Radiation Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Ahmed Mohyeldin
- Department of Neurosurgery, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Samuel Beck
- Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, Center for Systems and Synthetic Biology, The University of Texas at Austin, Austin, TX 78712, USA
| | - Kazuhiko Kurozumi
- Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan
| | - Toshihiko Kuroiwa
- Department of Neurosurgery, Osaka Medical College, Osaka 569-8686, Japan
| | - Ryoichi Iwata
- Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan
| | - Akio Asai
- Department of Neurosurgery, Kansai Medical University, Osaka 573-1191, Japan
| | - Jonghwan Kim
- Department of Molecular Biosciences, Institute for Cellular and Molecular Biology, Center for Systems and Synthetic Biology, The University of Texas at Austin, Austin, TX 78712, USA
| | - Erik P Sulman
- Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Shi-Yuan Cheng
- The Ken & Ruth Davee Department of Neurology & Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - L James Lee
- Center for Affordable Nanoengineering of Polymeric Biomedical Devices, The Ohio State University, Columbus, OH 43210, USA; Center for Regenerative Medicine and Cell-Based Therapies, The Ohio State University, Columbus, OH 43210, USA; Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA
| | - Mitsutoshi Nakada
- Department of Neurosurgery, Kanazawa University, Kanazawa 920-8641, Japan
| | - Denis Guttridge
- Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
| | - Biplab DasGupta
- Division of Oncology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45242, USA
| | - Violaine Goidts
- Division of Molecular Genetics, German Cancer Research Center, 69120 Heidelberg, Germany
| | - Krishna P Bhat
- Department of Translational Molecular Pathology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Ichiro Nakano
- Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL 35294, USA; UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
| |
Collapse
|
69
|
Min Q, Cheng SY, Xi JF, Ma J, Xin TR, Xia B, Zou ZW. Expression Patterns of Three Genes Under Short and Long Term Cold Exposure in Thitarodes pui (Lepidoptera: Hepialidae), A Host of Ophiocordyceps sinensis. Cryo Letters 2016; 37:432-439. [PMID: 28072431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
UNLABELLED BACKGROUND: Thitarodes larvae are the host of the caterpillar fungus Ophiocordyceps sinensis. Low temperature is the main environmental limitation for larvae growth. OBJECTIVE To better understand the cold adaption process in T. pui larvae, the expression patterns of trehalose-6-phosphate synthase (TpTPS), heat shock protein 70 (TpHSP70), and heat shock protein 90 (TpHSP90) were investigated upon short and long-term exposure to 0°C. MATERIALS AND METHODS The 6th instar T. pui larvae were collected in July 2013. TpTPS was firstly sequenced and expression patterns of TpTPS, TpHSP70 and TpHSP90 were investigated using quantitative PCR. RESULTS Full-length cDNA of TpTPS was 3,012 bp, with an open reading frame of 2,472 bp and an encoding protein of 823 amino acids. TpTPS up-regulation was induced by cold exposure. TpHSP70 expression is altered by cold exposure, but remained low. TpHSP90 expression was obviously up regulated in long-term cold stimulation. CONCLUSION All three genes (TpTPS, TpHSP70 and TpHSP90) have likely contributed to cold tolerance in T. pui larvae, TpTPS and TpHSP90 potentially being more important.
Collapse
Affiliation(s)
- Q Min
- School of Life Science, Nanchang University, Nanchang, China
| | - S Y Cheng
- School of Life Science, Nanchang University, Nanchang, China
| | - J F Xi
- School of Life Science, Nanchang University, Nanchang, China
| | - J Ma
- School of Life Science, Nanchang University, Nanchang, China
| | - T R Xin
- School of Life Science, Nanchang University, Nanchang, China
| | - B Xia
- School of Life Science, Nanchang University, Nanchang, China
| | - Z W Zou
- School of Life Science, Nanchang University, Nanchang, China.
| |
Collapse
|
70
|
Bell JB, Eckerdt F, Arslan AD, Iqbal A, Alvarez AA, Cheng SY, Nakano I, Platanias LC. Abstract B26: MAPK-interacting kinase inhibition sensitizes glioblastoma and glioma stem cells to arsenic trioxide. Cancer Res 2015. [DOI: 10.1158/1538-7445.brain15-b26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Glioblastoma (GBM) is the deadliest primary brain tumor with a median survival of around one year. Arsenic trioxide (ATO) is an emerging therapy for the treatment of GBM and other malignant brain tumors. The cytotoxic effects of ATO are mainly mediated by the production of reactive oxygen species and induction of cell death pathways. However, glioma stem cells in heterogeneous GBM tumors impart resistance by activation of survival pathways, thereby preventing therapeutic responses to cytotoxic agents such as ATO. We have previously shown that ATO responses in leukemia are antagonized by the MAPK-interacting kinases (MNKs), which activate protein translation and survival pathways including the eukaryotic translation initiation factor 4E (eIF4E) in response to ATO treatment. Yet, the role of MNK signaling in GBM and glioma stem cells and the potential of using MNK inhibitors to sensitize GBM to ATO has not been explored. In this study, we sought to determine the mechanisms by which MNK signaling regulates arsenic trioxide responses in GBM and glioma stem cells.
GBM cell lines were treated with ATO in the presence or absence of MNK inhibitors or siRNA against MNK isoforms. Western blots of treated samples were analyzed with antibodies against phosphorylated eIF4E, the key downstream effector of the MNKs. Following treatment with ATO and MNK inhibitors, proliferation rate and apoptosis were determined by WST-1 assay and Annexin V-FITC/PI staining. GBM cell lines were grown under stem cell conditions and subjected to qPCR and flow cytometry to monitor CD44 expression and aldehyde dehydrogenase (ALDH) activity, both markers of stemness. Patient-derived glioma stem cell lines displaying mesenchymal-like phenotype were treated with ATO and MNK inhibitors and analyzed by neurosphere formation assay.
Treatment of GBM cell lines with ATO resulted in MNK activation and induction of eIF4E phosphorylation in a MNK1-depedent manner. Furthermore, MNK inhibition sensitized GBM cells to the anti-proliferative and pro-apoptotic effects of ATO. Knockdown of MNK1 in GBM cell lines grown under stem cell conditions decreased neurosphere formation. Finally, pharmacological MNK inhibition sensitized mesenchymal-like glioma stem cells to ATO. Our results suggest ATO in combination with MNK inhibition might represent a new approach for the treatment of GBM, in particular the therapy-resistant glioma stem cell subpopulation.
Citation Format: Jonathan B. Bell, Frank Eckerdt, Ahmet Dirim Arslan, Asneha Iqbal, Angel A. Alvarez, Shi-Yuan Cheng, Ichiro Nakano, Leonidas C. Platanias. MAPK-interacting kinase inhibition sensitizes glioblastoma and glioma stem cells to arsenic trioxide. [abstract]. In: Proceedings of the AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2015;75(23 Suppl):Abstract nr B26.
Collapse
Affiliation(s)
- Jonathan B. Bell
- 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL,
| | - Frank Eckerdt
- 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL,
| | - Ahmet Dirim Arslan
- 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL,
| | - Asneha Iqbal
- 2Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL,
| | - Angel A. Alvarez
- 3Northwestern University Feinberg School of Medicine, Chicago, IL,
| | - Shi-Yuan Cheng
- 3Northwestern University Feinberg School of Medicine, Chicago, IL,
| | - Ichiro Nakano
- 4The Ohio State University James Comprehensive Cancer Center, Columbus, OH
| | - Leonidas C. Platanias
- 1Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL,
| |
Collapse
|
71
|
Cheng SY, Li LL, Yuan HH, Xu F, Cheng H. Molecular cloning and characterization of GbMECT and GbMECP gene promoters from Ginkgo biloba. Genet Mol Res 2015; 14:15112-22. [PMID: 26634474 DOI: 10.4238/2015.november.24.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Ginkgolides are key pharmaceutical components in Ginkgo biloba. Using the cDNA sequence of the MECP and MECT genes to design primers, we obtained the promoters of these genes from Ginkgo genomic DNA using the genome walking method. The two promoters were 744 and 982 bp in length, respectively. The cis-elements of the GbMECPs and GbMECT promoters were predicted and analyzed using the plant cis-acting regulatory element database. We found major cis-elements in the sequence of the GbMECT and GbMECPs promoters. The GbMECP promoter contains six TATA boxes and eight CAAT boxes. The GbMECT contains five TATA boxes and seven CAAT boxes. Furthermore, some cis-elements in the promoters of GbMECPs and GbMECT included hormone and light-regulated elements, UB-B-induced elements, and stress-related dehydration-responsive elements. Expression analysis results showed that the MECP gene is mainly involved in responses to CCC (cycocel) and UV-B, and that MECT is mainly involved in responses to wounding treatment. These results also showed that the expression model was consistent with the cis-elements present. During the annual growth cycle, the level of GbMECPs was significantly correlated with terpene lactones accumulation in leaves. A fitted quadratic curve showed the best model for correlating GbMECPs with terpene lactones in leaves. These results will help us to understand the transcriptional regulatory mechanisms involved in key gene expression and ginkgolide accumulation in G. biloba.
Collapse
Affiliation(s)
- S Y Cheng
- School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, Hubei, China
| | - L L Li
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratories, Hubei, Huanggang, China
| | - H H Yuan
- School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, Hubei, China
| | - F Xu
- College of Horticulture and gardening, Yangtze University, Jingzhou, Hubei, China
| | - H Cheng
- School of Biology and Pharmaceutical Engineering, Wuhan Polytechnic University, Wuhan, Hubei, China
| |
Collapse
|
72
|
Chandran UR, Luthra S, Santana-Santos L, Mao P, Kim SH, Minata M, Li J, Benos PV, DeWang M, Hu B, Cheng SY, Nakano I, Sobol RW. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells. Genom Data 2015; 5:333-336. [PMID: 26251826 PMCID: PMC4523279 DOI: 10.1016/j.gdata.2015.07.007] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Tumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG subtypes is poorly characterized. Previously we identified and characterized two mutually exclusive GSC subtypes with distinct activated signaling pathways and biological phenotypes. One GSC subtype presented with a gene signature resembling Proneural (PN) HGG, whereas the other was similar to mesenchymal (Mes) HGG. Classical HGG-derived GSCs were sub-classified as either one of these two subtypes. Differential mRNA expression analysis of PN and Mes GSCs identified 5796 differentially expressed genes, revealing a pronounced correlation with the corresponding PN or Mes HGGs. Mes GSCs displayed more aggressive phenotypes in vitro and as intracranial xenografts in mice. Further, Mes GSCs were markedly resistant to radiation compared with PN GSCs. Expression of ALDH1A3 — one of the most up-regulated Mes representative genes and a universal cancer stem cell marker in non-brain cancers — was associated with self-renewal and a multi-potent stem cell population in Mes but not PN samples. Moreover, inhibition of ALDH1A3 attenuated the growth of Mes but not PN GSCs in vitro. Lastly, radiation treatment of PN GSCs up-regulated Mes-associated markers and down-regulated PN-associated markers, whereas inhibition of ALDH1A3 attenuated an irradiation-induced gain of Mes identity in PN GSCs in vitro. Taken together, our data suggest that two subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma heterogeneity and highlight previously unidentified roles of ALDH1A3-associated signaling that promotes aberrant proliferation of Mes HGGs and GSCs. Inhibition of ALDH1A3-mediated pathways therefore might provide a promising therapeutic approach for a subset of HGGs with the Mes signature. Here, we describe the gene expression analysis, including pre-processing methods for the data published by Mao and colleagues in PNAS [1], integration of microarray data from this study with The Cancer Genome Atlas (TCGA) glioblastoma data and also with another published study. The raw CEL files and processed data were submitted to Gene Expression Omnibus (GEO) under the accession GSE67089.
Collapse
Affiliation(s)
- Uma R Chandran
- Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
| | - Soumya Luthra
- Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
| | - Lucas Santana-Santos
- Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA ; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Ping Mao
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA ; Department of Neurosurgery, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China
| | - Sung-Hak Kim
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
| | - Mutsuko Minata
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
| | - Jianfeng Li
- Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15216, USA ; University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213-1863, USA ; University of South Alabama Mitchell Cancer Institute, Mobile, AL 36604, USA
| | - Panayiotis V Benos
- Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA ; Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA
| | - Mao DeWang
- Department of Neurosurgery, First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China
| | - Bo Hu
- Department of Neurology & Northwestern Brain Tumor Institute, Center for Genetic Medicine, Robert Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Shi-Yuan Cheng
- Department of Neurology & Northwestern Brain Tumor Institute, Center for Genetic Medicine, Robert Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Ichiro Nakano
- Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA ; James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
| | - Robert W Sobol
- Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15216, USA ; University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213-1863, USA ; Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15216, USA ; University of South Alabama Mitchell Cancer Institute, Mobile, AL 36604, USA
| |
Collapse
|
73
|
Lu S, Lu KN, Cheng SY, Hu B, Ma X, Nystrom N, Lu X. Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets. PLoS Comput Biol 2015; 11:e1004257. [PMID: 26317392 PMCID: PMC4552843 DOI: 10.1371/journal.pcbi.1004257] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Accepted: 03/24/2015] [Indexed: 02/07/2023] Open
Abstract
An important goal of cancer genomic research is to identify the driving pathways underlying disease mechanisms and the heterogeneity of cancers. It is well known that somatic genome alterations (SGAs) affecting the genes that encode the proteins within a common signaling pathway exhibit mutual exclusivity, in which these SGAs usually do not co-occur in a tumor. With some success, this characteristic has been utilized as an objective function to guide the search for driver mutations within a pathway. However, mutual exclusivity alone is not sufficient to indicate that genes affected by such SGAs are in common pathways. Here, we propose a novel, signal-oriented framework for identifying driver SGAs. First, we identify the perturbed cellular signals by mining the gene expression data. Next, we search for a set of SGA events that carries strong information with respect to such perturbed signals while exhibiting mutual exclusivity. Finally, we design and implement an efficient exact algorithm to solve an NP-hard problem encountered in our approach. We apply this framework to the ovarian and glioblastoma tumor data available at the TCGA database, and perform systematic evaluations. Our results indicate that the signal-oriented approach enhances the ability to find informative sets of driver SGAs that likely constitute signaling pathways. An important goal of studying cancer genomics is to identify critical pathways that, when perturbed by somatic genomic alterations (SGAs) such as somatic mutations, copy number alterations and epigenomic alterations, cause cancers and underlie different clinical phenotypes. In this study, we present a framework for discovering perturbed signaling pathways in cancers by integrating genome alteration data and transcriptomic data from the Cancer Genome Atlas (TCGA) project. Since gene expression in a cell is regulated by cellular signaling systems, we used transcriptomic changes to reveal perturbed cellular signals in each tumor. We then combined the genomic alteration data to search for SGA events across multiple tumors that affected a common signal, thus identifying the candidate members of cancer pathways. Our results demonstrate the advantage of the signal-oriented pathway approach over previous methods.
Collapse
Affiliation(s)
- Songjian Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
- * E-mail:
| | - Kevin N. Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Shi-Yuan Cheng
- Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
| | - Bo Hu
- Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
| | - Xiaojun Ma
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| | - Nicholas Nystrom
- Pittsburgh Supercomputing Center, Pittsburgh, Pennsylvania, United States of America
| | - Xinghua Lu
- Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America
| |
Collapse
|
74
|
Sunghak K, Violaine RG, Cheng SY, Ichiro N. Abstract B72: Serine/threonine kinase MLK4 is a master regulator for proneural-mesenchymal transformation of glioma stem cells. Cancer Res 2015. [DOI: 10.1158/1538-7445.chtme14-b72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
High-grade glioma is a highly aggressive form of brain cancer associated with a poor prognosis. Recently, we identified that mesenchymal glioma stem cells (Mes GSCs) of HGG are linked to radiation resistance and proneural (PN) GSCs acquire Mes identity via radiation treatment. Here we performed a combined kinome-wide RNA interference screen with genome wide expression analysis to identify kinase-encoding genes that are essential for mesenchymal identity of GSCs. Through this stepwise screening with patient-derived GSC samples, we identified the serine/threonine kinase MLK4 as a key regulator for Mes GSC survival and cell cycle progression in vitro and tumor initiation and propagation in vivo. In addition, overexpression of MLK4 promotes, while both its gene-specific shRNA and pharmacological inhibition attenuate, proneural-mesenchymal transformation (PMT) of GSCs. In patient-derived GSCs, expression of MLK4 protein positively correlated with endogenous EGFRvIII expression and the in vivo growth of mouse xenografts derived from glioma cells with EGFRvIII expression was prominently inhibited by MLK4 knockdown. MLK4-overexpressing PN GSCs acquired radiation resistance, while MLK4 elimination by shRNA radiosensitized Mes GSCs. Patients with a higher MLK4 expression showed reduced survival in CD44-high populations. Collectively, these data indicate that MLK4 as a plausible target for therapy against Mes GBM as well as post-irradiation PN GBM.
Citation Format: Kim Sunghak, Rosenstiel-Goidts Violaine, Shi-Yuan Cheng, Nakano Ichiro. Serine/threonine kinase MLK4 is a master regulator for proneural-mesenchymal transformation of glioma stem cells. [abstract]. In: Abstracts: AACR Special Conference on Cellular Heterogeneity in the Tumor Microenvironment; 2014 Feb 26-Mar 1; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2015;75(1 Suppl):Abstract nr B72. doi:10.1158/1538-7445.CHTME14-B72
Collapse
Affiliation(s)
| | | | - Shi-Yuan Cheng
- 3Northwestern University Feinberg School of Medicine, Chicago, IL
| | | |
Collapse
|
75
|
Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, Li Z, Xie B, Gao WQ, Sarkaria JN, Raizer JJ, James CD, Parsa AT, Hu B, Cheng SY. Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α. Neuro Oncol 2014; 17:832-42. [PMID: 25468898 DOI: 10.1093/neuonc/nou323] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2007] [Accepted: 10/30/2014] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Dedicator of cytokinesis 1 (Dock1 or Dock180), a bipartite guanine nucleotide exchange factor for Rac1, plays critical roles in receptor tyrosine kinase-stimulated cancer growth and invasion. Dock180 activity is required in cell migration cancer tumorigenesis promoted by platelet derived growth factor receptor (PDGFR) and epidermal growth factor receptor. METHODS To demonstrate whether PDGFRα promotes tumor malignant behavior through protein kinase A (PKA)-dependent serine phosphorylation of Dock180, we performed cell proliferation, viability, migration, immunoprecipitation, immunoblotting, colony formation, and in vivo tumorigenesis assays using established and short-term explant cultures of glioblastoma cell lines. RESULTS Stimulation of PDGFRα results in phosphorylation of Dock180 at serine residue 1250 (S1250), whereas PKA inhibitors H-89 and KT5720 oppose this phosphorylation. S1250 locates within the Rac1-binding Dock homology region 2 domain of Dock180, and its phosphorylation activates Rac1, p-Akt, and phosphorylated extracellular signal-regulated kinase 1/2, while promoting cell migration, in vitro. By expressing RNA interference (RNAi)-resistant wild-type Dock180, but not mutant Dock180 S1250L, we were able to rescue PDGFRα-associated signaling and biological activities in cultured glioblastoma multiforme (GBM) cells that had been treated with RNAi for suppression of endogenous Dock180. In addition, expression of the same RNAi-resistant Dock180 rescued an invasive phenotype of GBM cells following intracranial engraftment in immunocompromised mice. CONCLUSION These data describe an important mechanism by which PDGFRα promotes glioma malignant phenotypes through PKA-dependent serine phosphorylation of Dock180, and the data thereby support targeting the PDGFRα-PKA-Dock180-Rac1 axis for treating GBM with molecular profiles indicating PDGFRα signaling dependency.
Collapse
Affiliation(s)
- Haizhong Feng
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Yanxin Li
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Yuhua Yin
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Weiwei Zhang
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Yanli Hou
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Lei Zhang
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Zuoqing Li
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Baoshu Xie
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Wei-Qiang Gao
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Jann N Sarkaria
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Jeffery J Raizer
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - C David James
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Andrew T Parsa
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Bo Hu
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| | - Shi-Yuan Cheng
- State Key Laboratory of Oncogenes and Related Genes, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (H.F., W.Z., Y.H., L.Z., Z.L., W.-Q.G., S.-Y.C.); Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (H.F., J.J.R., B.H., S.-Y.C.); Key Laboratory of Pediatric Hematology and Oncology Ministry of Health, Pediatric Translational Medicine Institute, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.L.); Department of Neurological Surgery (Y.Y., B.X.); Department of Radiotherapy, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China (Y.H.); Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (J.N.S.); Department of Neurological Surgery, Northwestern Brain Tumor Institute, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois (C.D.J., A.T.P.)
| |
Collapse
|
76
|
Zhang W, Hou L, Yan L, Zhang W, Wang MY, Cheng SY. The US Chinese Anti-Cancer Association and the National Foundation for Cancer Research recognize five young Chinese investigators with the 2014 USCACA-NFCR Scholar Awards. Chin J Cancer 2014. [PMCID: PMC4244313 DOI: 10.5732/cjc.014.10221] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Wei Zhang
- Department of Pediatrics, University of Illinois, Chicago, IL 60612, USA;
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553, USA;
| | - Lifang Hou
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553, USA;
- Department of Preventive Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA;
| | - Li Yan
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553, USA;
- Beijing Cancer Hospital and Institute, Peking University School of Oncology, Beijing 100142, China;
| | - Wei Zhang
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553, USA;
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
| | - Michael Yi Wang
- National Foundation for Cancer Research, Bethesda, MD 20814, USA;
| | - Shi-Yuan Cheng
- US Chinese Anti-Cancer Association, Los Angeles, Martinez, CA 94553, USA;
- Department of Neurology & Northwestern Brain Tumor Institute, Center of Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA.
| |
Collapse
|
77
|
Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther 2014; 13:2919-29. [PMID: 25313012 DOI: 10.1158/1535-7163.mct-14-0306] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM.
Collapse
Affiliation(s)
- Yasuyuki Yoshida
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California
| | - Tomoko Ozawa
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California
| | - Tsun-Wen Yao
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California. Department of Pediatrics, University of California San Francisco, San Francisco, California
| | - Wang Shen
- NewGen Therapeutics, Inc., Menlo Park, California
| | - Dennis Brown
- NewGen Therapeutics, Inc., Menlo Park, California
| | - Andrew T Parsa
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jeffrey J Raizer
- Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Shi-Yuan Cheng
- Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Alexander H Stegh
- Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Andrew P Mazar
- Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Francis J Giles
- Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
| | - Jann N Sarkaria
- Department of Radiation Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Nicholas Butowski
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California
| | - Theodore Nicolaides
- Department of Neurological Surgery, University of California San Francisco, San Francisco, California. Department of Pediatrics, University of California San Francisco, San Francisco, California.
| | - C David James
- Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. Northwestern Medicine Developmental Therapeutics Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
| |
Collapse
|
78
|
Alvarez A, Ugolkov A, Gaisina I, Kozikowski AP, Joshi K, Kim S, Nakano I, Raizer JJ, Mazar AP, Hu B, Cheng SY. Abstract 1941: GSK3 signaling is critical to glioma stem cell growth and survival. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-1941] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
GSK3 is an attractive therapeutic target in cancer, known for its role in regulating proliferation, differentiation, metabolism, and apoptosis. Previous studies demonstrate the effectiveness of GSK3 inhibition on established glioma cell lines and patient-derived glioma stem cell lines in vitro and in vivo. In glioma cell lines, GSK3 inhibition induces apoptosis through c-MYC activation, mitochondrial destabilization, and reduction of NF-κB activity. We have characterized a novel set of GSK3 inhibitors for their ability to inhibit glycogen synthase phosphorylation, reduce levels of XIAP, and induce cell death in cancer cells. However, it is uncertain if this mechanism is functional with respect to cancer stem cells and glioma tumor subtype. The need to investigate the mechanistic effects of GSK3 in cancer stem cells is important given their malignancy, innate resistance to therapy, and tumorigenicity. Moreover, the intracellular signaling and transcription networks may differ in glioma stem cells, particularly among cells with different subtypes. We have recently demonstrated that cancer stem cells isolated from glioma patients can be segregated into either a proneural or mesenchymal subtype based on their gene expression pattern. The oncogenic activity of genes like c-MYC in glioma stem cells and differences between glioma stem cell subtypes, such as NF-κB activation, raises questions as to whether GSK3 inhibition will be effective against both subtypes and if their effects utilize distinct mechanisms of inhibition. In this study, we examine the effects of two established and two novel GSK3 inhibitors on glioma stem cells with respect to tumor subtype and investigate their mechanisms of action. Our in vitro data shows that GSK3 inhibition significantly reduces growth and causes cell death in both proneural and mesenchymal glioma stem cells. Using a glioma stem cell xenograft model, we test the effectiveness of GSK3 inhibition as a single agent and in conjunction with clinically-approved chemotherapeutic agents. The characterization of cancer stem cell inhibitors and their effectiveness in different tumor subtypes has significant clinical implications. Our work supports the therapeutic potential of novel GSK3 inhibitors for the treatment of malignant gliomas.
Note: This abstract was not presented at the meeting.
Citation Format: Angel Alvarez, Andrey Ugolkov, Irina Gaisina, Alan P. Kozikowski, Kaushal Joshi, Sunghak Kim, Ichiro Nakano, Jeffrey J. Raizer, Andrew P. Mazar, Bo Hu, Shi-Yuan Cheng. GSK3 signaling is critical to glioma stem cell growth and survival. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1941. doi:10.1158/1538-7445.AM2014-1941
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Bo Hu
- 1Northwestern University, Chicago, IL
| | | |
Collapse
|
79
|
Hou WX, Cheng SY, Liu ST, Shi BM, Shan AS. Dietary Supplementation of Magnesium Sulfate during Late Gestation and Lactation Affects the Milk Composition and Immunoglobulin Levels in Sows. Asian-Australas J Anim Sci 2014; 27:1469-77. [PMID: 25178299 PMCID: PMC4150180 DOI: 10.5713/ajas.2014.14190] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/11/2014] [Revised: 05/01/2014] [Accepted: 06/10/2014] [Indexed: 11/27/2022]
Abstract
This experiment was conducted to investigate the effects of dietary supplementation of magnesium sulfate (MgSO4) during late gestation and lactation on sow and litter performance, fecal moisture, blood biochemistry parameters, immunoglobulin levels and milk composition in sows. Forty-eight sows (Yorkshire×Landrace, 4th to 5th parity) were randomly allocated to 1 of 4 dietary treatments supplemented with 0, 200, 400, or 600 mg/kg MgSO4 (n = 12). The experiment started on day 90 of gestation and continued through day 21 of lactation. Blood samples were collected on day 107 of gestation, day 0 (farrowing) and 21 (weaning) of lactation for the analyses of the blood biochemistry parameters and immunoglobulin levels. The colostrum and milk samples were obtained on day 0 and 14 of lactation, respectively. Fecal samples were collected from the sows on day 107 of gestation as well as day 7 and 20 of lactation to determine fecal moisture content. The results showed that the survival percentage of piglets and the litter weight at weaning were decreased linearly (p<0.05) and other parameters of the sow or litter performance were not influenced (p>0.05) by MgSO4 supplementation. The fecal moisture content of the sows were increased (p<0.05) linearly as dietary MgSO4 increased on day 7 and 20 of lactation. Supplementation with MgSO4 increased the plasma magnesium (Mg) level linearly (p<0.05) and had a trend to increase total protein level (p>0.05 and p<0.10). However, an increase in the dietary MgSO4 level resulted in a linear decrease in the colostrum fat content (p<0.05). Dietary MgSO4 supplementation enhanced the immunoglobulin G (IgG) level (linear, p<0.05) in plasma on day of farrowing and immunoglobulin A (IgA) level in colostrum (quadratic, p<0.05) and milk (linear, p<0.05) of the sows. These results indicated that supplementation with MgSO4 during late gestation and lactation may have the potential to prevent sow constipation, but may also result in some negative effects.
Collapse
|
80
|
Abstract
In recent years, it has become increasingly apparent that noncoding RNAs (ncRNA) are of crucial importance for human cancer. The functional relevance of ncRNAs is particularly evident for microRNAs (miRNAs) and long noncoding RNAs (lncRNAs). miRNAs are endogenously expressed small RNA sequences that act as post-transcriptional regulators of gene expression and have been extensively studied for their roles in cancers, whereas lncRNAs are emerging as important players in the cancer paradigm in recent years. These noncoding genes are often aberrantly expressed in a variety of human cancers. However, the biological functions of most ncRNAs remain largely unknown. Recently, evidence has begun to accumulate describing how ncRNAs are dysregulated in cancer and cancer stem cells, a subset of cancer cells harboring self-renewal and differentiation capacities. These studies provide insight into the functional roles that ncRNAs play in tumor initiation, progression, and resistance to therapies, and they suggest ncRNAs as attractive therapeutic targets and potentially useful diagnostic tools.
Collapse
Affiliation(s)
- Tianzhi Huang
- The Ken & Ruth Davee Department of Neuro-logy, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA. ,
| | | | | | | |
Collapse
|
81
|
Zhang W, Cheng SY, Hou LF, Yan L, Tong YG. Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting. Chin J Cancer 2014; 33:371-5. [PMID: 25096543 PMCID: PMC4135365 DOI: 10.5732/cjc.014.10110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.
Collapse
Affiliation(s)
- Wei Zhang
- Executive Committee of the US Chinese Anti-Cancer Association (USCACA), Martinez, CA 94553, USA; Department of Pediatrics, University of Illinois at Chicago, Chicago, IL 60612, USA.
| | | | | | | | | |
Collapse
|
82
|
Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJA, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J Clin Invest 2014; 124:3741-56. [PMID: 25061874 DOI: 10.1172/jci73093] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2013] [Accepted: 06/06/2014] [Indexed: 12/31/2022] Open
Abstract
Aberrant activation of EGFR in human cancers promotes tumorigenesis through stimulation of AKT signaling. Here, we determined that the discoidina neuropilin-like membrane protein DCBLD2 is upregulated in clinical specimens of glioblastomas and head and neck cancers (HNCs) and is required for EGFR-stimulated tumorigenesis. In multiple cancer cell lines, EGFR activated phosphorylation of tyrosine 750 (Y750) of DCBLD2, which is located within a recently identified binding motif for TNF receptor-associated factor 6 (TRAF6). Consequently, phosphorylation of DCBLD2 Y750 recruited TRAF6, leading to increased TRAF6 E3 ubiquitin ligase activity and subsequent activation of AKT, thereby enhancing EGFR-driven tumorigenesis. Moreover, evaluation of patient samples of gliomas and HNCs revealed an association among EGFR activation, DCBLD2 phosphorylation, and poor prognoses. Together, our findings uncover a pathway in which DCBLD2 functions as a signal relay for oncogenic EGFR signaling to promote tumorigenesis and suggest DCBLD2 and TRAF6 as potential therapeutic targets for human cancers that are associated with EGFR activation.
Collapse
|
83
|
Li LL, Cheng H, Yuan HH, Xu F, Cheng SY, Cao FL. Functional characterization of the Ginkgo biloba chalcone synthase gene promoter in transgenic tobacco. Genet Mol Res 2014; 13:3446-60. [PMID: 24841790 DOI: 10.4238/2014.april.30.6] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
The regulative sequence (2273 bp) of the chalcone synthase gene promoter of biloba was cloned by genomic walking. A 2273-bp promoter 5' upstream translation start site of GbCHS was cloned and designated as GbCHSP. pBI121+CHSP:GUS and pBI121-35S:GUS were constructed and transformed into tobacco by LBA4404. We found that GbCHSP could drive transient expression of GUS in tobacco and differentially expressed in root, stem and leaf tissues of this plant. GUS activity regulated by the CHSP promoter were located in tissues (apical meristems) at the growing points of roots and stems. pBI121+CHSP:GUS could be induced by wounding, copper, UV-B, abscisic acid, and ethephon treatments of transgenic seedlings. This activity was weakly inhibited by gibberellin. Deletion analysis of the CHSP promoter in transgenic tobacco showed that CHSP1 complete promoter conferred a GUS expression and activity similar to that of 35 S(CaMV). GUS activity dropped dramatically when there were CHSP4, CHSP5 constructs and was almost totally absent when the CHSP6 construct was present. We conclude that the upstream sequence -1548 to -306 of GbCHSP is the main region for transcriptional regulation of the CHS gene and that it is activated by hormone and stress factors in G. biloba. These results will help us to understand the transcriptional regulatory mechanisms involved in GbCHS expression and flavonoid accumulation in G. biloba.
Collapse
Affiliation(s)
- L L Li
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratory, Huanggang Normal University, Huanggang, Hubei, China
| | - H Cheng
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratory, Huanggang Normal University, Huanggang, Hubei, China
| | - H H Yuan
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratory, Huanggang Normal University, Huanggang, Hubei, China
| | - F Xu
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratory, Huanggang Normal University, Huanggang, Hubei, China
| | - S Y Cheng
- Economic Forest Germplasm Improvement and Comprehensive Utilization of Resources of Hubei Key Laboratory, Huanggang Normal University, Huanggang, Hubei, China
| | - F L Cao
- College of Forest Resources and Environment, Nanjing Forestry University, Nanjing, Jiangsu, China
| |
Collapse
|
84
|
Ma HI, Hueng DY, Shui HA, Han JM, Wang CH, Lai YH, Cheng SY, Xiao X, Chen MT, Yang YP. Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation. Int J Mol Sci 2014; 15:4393-414. [PMID: 24625664 PMCID: PMC3975403 DOI: 10.3390/ijms15034393] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Revised: 02/08/2014] [Accepted: 02/19/2014] [Indexed: 12/24/2022] Open
Abstract
Glioblastoma multiforme (GBM) is the most malignant cancer in the central nervous system with poor clinical prognosis. In this study, we investigated the therapeutic effect of an anti-cancer protein, decorin, by delivering it into a xenograft U87MG glioma tumor in the brain of nude mice through an adeno-associated viral (AAV2) gene delivery system. Decorin expression from the AAV vector in vitro inhibited cultured U87MG cell growth by induction of cell differentiation. Intracranial injection of AAV-decorin vector to the glioma-bearing nude mice in vivo significantly suppressed brain tumor growth and prolonged survival when compared to control non-treated mice bearing the same U87MG tumors. Proteomics analysis on protein expression profiles in the U87MG glioma cells after AAV-mediated decorin gene transfer revealed up- and down-regulation of important proteins. Differentially expressed proteins between control and AAV-decorin-transduced cells were identified through MALDI-TOF MS and database mining. We found that a number of important proteins that are involved in apoptosis, transcription, chemotherapy resistance, mitosis, and fatty acid metabolism have been altered as a result of decorin overexpression. These findings offer valuable insight into the mechanisms of the anti-glioblastoma effects of decorin. In addition, AAV-mediated decorin gene delivery warrants further investigation as a potential therapeutic approach for brain tumors.
Collapse
Affiliation(s)
- Hsin-I Ma
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Dueng-Yuan Hueng
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Hao-Ai Shui
- Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Jun-Ming Han
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Chi-Hsien Wang
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| | - Ying-Hsiu Lai
- Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei 11217, Taiwan.
| | - Shi-Yuan Cheng
- Department of Neurology, Northwestern Brain Tumor Institute. The Robert H. Lurie Comprehensive Cancer Center, Center of Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
| | - Xiao Xiao
- Division of Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
| | - Ming-Teh Chen
- School of Medicine, National Yang-Ming University, Taipei 11221, Taiwan.
| | - Yi-Ping Yang
- Department of Neurological Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 11490, Taiwan.
| |
Collapse
|
85
|
Hou L, Yan L, Zhang W, Wang MY, Cheng SY. Four outstanding young Chinese scientists received the 2013 Scholar Award from the US Chinese Anti-Cancer Association and the National Foundation for Cancer Research. Chin J Cancer 2013. [PMCID: PMC3870845 DOI: 10.5732/cjc.013.10228] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Lifang Hou
- Department of Preventive Medicine, Center of Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA;
- US Chinese Anti-Cancer Association, Los Angeles, CA 90048, USA;
| | - Li Yan
- US Chinese Anti-Cancer Association, Los Angeles, CA 90048, USA;
| | - Wei Zhang
- Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA;
- US Chinese Anti-Cancer Association, Los Angeles, CA 90048, USA;
| | - Michael Yi Wang
- National Foundation for Cancer Research, Bethesda, MD 20814, USA.
| | - Shi-Yuan Cheng
- Department of Neurology & Northwestern Brain Tumor Institute, Center of Genetic Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL 60611, USA;
- US Chinese Anti-Cancer Association, Los Angeles, CA 90048, USA;
| |
Collapse
|
86
|
Du J, Cheng SY, Hou WX, Shi BM, Shan AS. Effectiveness of maifanite in reducing the detrimental effects of cadmium on growth performance, cadmium residue, hematological parameters, serum biochemistry, and the activities of antioxidant enzymes in pigs. Biol Trace Elem Res 2013; 155:49-55. [PMID: 23904328 DOI: 10.1007/s12011-013-9769-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Accepted: 07/22/2013] [Indexed: 10/26/2022]
Abstract
This study was conducted to investigate the toxicity of cadmium and to evaluate the effectiveness of maifanite in preventing cadmium-induced adverse effects. Thirty-two crossbred pigs (Duroc × Landrace × Large white, sex balanced, 17.25 ± 0.07 kg average body weight) were randomly allotted to one of four dietary treatments in a 2 × 2 factorial arrangement, with eight replicates per treatment and one pig per replicate. The dietary treatments included two cadmium (as CdCl2) doses (0.32 and 30.49 mg/kg) and two maifanite doses (0 and 1%). The results showed that pigs treated with cadmium decreased their average daily feed intake (P < 0.05) and increased (P < 0.05) the feed/gain ratio. Cadmium was found in the tissues of pigs that were fed with cadmium-contaminated diets, but the level of cadmium was much lower when maifanite was added to the cadmium-contaminated diets. Ingestion of diets that were artificially contaminated with cadmium (30.49 mg/kg of cadmium) reduced (P < 0.05) the number of lymphocytes, the total erythrocyte count, the hemoglobin level, and the hematocrit. However, the activities of serum aspartate aminotransferase and gamma glutamyltransferase were increased (P < 0.05). The total protein level was lower (P < 0.05) in pigs fed with cadmium-contaminated diets. The contents of malondialdehyde increased (P < 0.05), while the total antioxidant capacity and the activities of total superoxide dismutase, glutathione peroxidase, glutathione S-transferase, and catalase decreased (P < 0.05) in pigs fed with cadmium-contaminated diets. Dietary addition of maifanite can, to some extent, prevent the negative effects associated with feeding cadmium diets (30.49 mg/kg of cadmium) to pigs.
Collapse
Affiliation(s)
- J Du
- Institute of Animal Nutrition, Northeast Agricultural University, Harbin, China
| | | | | | | | | |
Collapse
|
87
|
Xu F, Huang XH, Li LL, Deng G, Cheng H, Rong XF, Li JB, Cheng SY. Molecular cloning and characterization of GbDXS and GbGGPPS gene promoters from Ginkgo biloba. Genet Mol Res 2013; 12:293-301. [PMID: 23408416 DOI: 10.4238/2013.february.4.3] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Ginkgolides are key pharmaceutical components in Ginkgo biloba leaves. 1-Deoxy-D-xylulose-5-phosphate synthase (GbDXS) and geranylgeranyl pyrophosphate (GbGGPPS) genes are critical genes involved in ginkgolide biosynthesis. In this study, the promoters of GbDXS and GGPPS, with 676 and 570 bp in length, respectively, were cloned by chromosome walking. The cis-elements of GbDXS and GbGGPPS promoters were predicted and analyzed by the plant cis-acting regulatory element (CARE) database. We found some major cis-elements in the sequence of GbDXS and GbGGPPS promoters. The GbDXS promoter has 3 TATA boxes, 10 CAAT boxes, 6 GATA boxes, and 1 I box. The GbGGPPS promoter has 1 TATA box, 6 CAAT boxes, 6 GATA boxes, and 4 I boxes. Furthermore, some stress-related cis-elements in the promoters of GbDXS and GbGGPPS were found to be light-regulated elements, including sequences over-represented in light-induced promoters (SORLIP1- AT), GATA box, and I box, a gibberellin-responsive element (WRKY), salicylic acid-induced (GT-1), cold- and dehydration-responsive (MYC-Core), and copper-inducible (CURE-Core). Further analyses of these cis-elements will aid in elucidating the molecular mechanisms regulating the expression of the GbDXS and GbGGPPS genes during ginkgolide accumulation in G. biloba.
Collapse
Affiliation(s)
- F Xu
- College of Horticulture and Gardening, Yangtze University, Jingzhou, Hubei, China
| | | | | | | | | | | | | | | |
Collapse
|
88
|
Jiang L, Song L, Wu J, Yang Y, Zhu X, Hu B, Cheng SY, Li M. Bmi-1 promotes glioma angiogenesis by activating NF-κB signaling. PLoS One 2013; 8:e55527. [PMID: 23383216 PMCID: PMC3561301 DOI: 10.1371/journal.pone.0055527] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2012] [Accepted: 12/27/2012] [Indexed: 01/17/2023] Open
Abstract
Angiogenesis in glioma is associated with the poor prognosis of the disease and closely correlates with the highly invasive phenotype of glioma cells, which represents the most challenging impediment against the currently glioma treatments. Bmi-1, an onco-protein, has been implicated in the progression of various human cancers, including gliomas, whereas its role in glioma angiogenesis remains unclear. Our current study examined the effects of Bmi-1 on glioma angiogenesis in vitro as well as in vivo. We found that overexpression of Bmi-1 enhanced, whereas knockdown of Bmi-1 diminished, the capability of glioma cells to induce tubule formation and migration of endothelial cells and neovascularization in chicken chorioallantoic membrane. In vivo, Bmi-1 overexpression and knockdown, respectively, promoted and inhibited angiogenesis in orthotopically transplanted human gliomas. Furthermore, NF-κB activity and VEGF-C expression was induced by Bmi-1 overexpression, whereas Bmi-1 knockdown attenuated NF-κB signaling and decreased VEGF-C expression. Additionally suppression of NF-κB activity using a specific chemical inhibitor abrogated the NF-κB activation and the pro-angiogenic activities of glioma cells. Together, our data suggest that Bmi-1 plays an important role in glioma angiogenesis and therefore could represent a potential target for anti-angiogenic therapy against the disease.
Collapse
Affiliation(s)
- Lili Jiang
- Department of Pathophysiology, Guangzhou Medical University, Guangzhou, Guangdong, China
| | - Libing Song
- Department of Experimental Research, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
| | - Jueheng Wu
- Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
- Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Chinese Ministry of Education, Guangzhou, Guangdong, China
| | - Yi Yang
- Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
- Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Chinese Ministry of Education, Guangzhou, Guangdong, China
| | - Xun Zhu
- Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
- Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Chinese Ministry of Education, Guangzhou, Guangdong, China
| | - Bo Hu
- Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
| | - Shi-Yuan Cheng
- Department of Neurology, Northwestern Brain Tumor Institute, Center for Genetic Medicine and The Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America
| | - Mengfeng Li
- Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
- Key Laboratory of Tropical Disease Control (Sun Yat-sen University), Chinese Ministry of Education, Guangzhou, Guangdong, China
- * E-mail:
| |
Collapse
|
89
|
Jane EP, Premkumar DR, DiDomenico JD, Hu B, Cheng SY, Pollack IF. YM-155 potentiates the effect of ABT-737 in malignant human glioma cells via survivin and Mcl-1 downregulation in an EGFR-dependent context. Mol Cancer Ther 2013; 12:326-38. [PMID: 23325792 DOI: 10.1158/1535-7163.mct-12-0901] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Antiapoptotic proteins are commonly overexpressed in gliomas, contributing to therapeutic resistance. We recently reported that clinically achievable concentrations of the Bcl-2/Bcl-xL inhibitor ABT-737 failed to induce apoptosis in glioma cells, with persistent expression of survivin and Mcl-1. To address the role of these mediators in glioma apoptosis resistance, we analyzed the effects of YM-155, a survivin suppressant, on survival on a panel of glioma cell lines. YM-155 inhibited cell growth and downregulated survivin and Mcl-1 in a dose- and cell line-dependent manner. While U373, LN18, LNZ428, T98G, LN229, and LNZ308 cells exhibited an IC(50) of 10 to 75 nmol/L, A172 cells were resistant (IC(50) ∼ 250 nmol/L). No correlation was found between sensitivity to YM-155 and baseline expression of survivin or cIAP-1/cIAP-2/XIAP. However, strong correlation was observed between EGF receptor (EGFR) activation levels and YM-155 response, which was confirmed using EGFR-transduced versus wild-type cells. Because we postulated that decreasing Mcl-1 expression may enhance glioma sensitivity to ABT-737, we examined whether cotreatment with YM-155 promoted ABT-737 efficacy. YM-155 synergistically enhanced ABT-737-induced cytotoxicity and caspase-dependent apoptosis. Downregulation of Mcl-1 using short hairpin RNA also enhanced ABT-737-inducing killing, confirming an important role for Mcl-1 in mediating synergism between ABT-737 and YM-155. As with YM-155 alone, sensitivity to YM-155 and ABT-737 inversely correlated with EGFR activation status. However, sensitivity could be restored in highly resistant U87-EGFRvIII cells by inhibition of EGFR or its downstream pathways, highlighting the impact of EGFR signaling on Mcl-1 expression and the relevance of combined targeted therapies to overcome the multiple resistance mechanisms of these aggressive tumors.
Collapse
Affiliation(s)
- Esther P Jane
- Department of Neurosurgery, Children's Hospital of Pittsburgh, Pittsburgh, PA 15224, USA
| | | | | | | | | | | |
Collapse
|
90
|
Abstract
Phenotypic similarities have long been recognized between subpopulations of glioma and neural stem cells. Many of these similar properties, including the robust abilities to self-renew, migrate, and invade, are hallmarks of glioma cells that render them extremely aggressive. However, the molecular mechanisms underlying this character, particularly in glioma stem-like cells that drive this disease, remain poorly understood. Here, we report the results of a differential miRNA expression screen that compared glioma and neural stem cells, where we found that miR-204 was markedly downregulated in both types of cells. Mechanistic investigations revealed that miR-204 simultaneously suppressed self-renewal, stem cell-associated phenotype, and migration of glioma cells by targeting the stemness-governing transcriptional factor SOX4 and the migration-promoting receptor EphB2. Restoring miR-204 expression in glioma cells suppressed tumorigenesis and invasiveness in vivo and increased overall host survival. Further evaluation revealed that the miR-204 promoter was hypermethylated and that attenuating promoter methylation was sufficient to upregulate miR-204 in glioma cells. Together, our findings reveal miR-204 as a pivotal regulator of the development of stem cell-like phenotypes and cell motility in malignant glioma cells.
Collapse
Affiliation(s)
- Zhe Ying
- Department of Microbiology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China
| | | | | | | | | | | | | | | | | | | |
Collapse
|
91
|
Abstract
Platelet-derived growth factors (PDGFs) and their receptors were identified and purified decades ago. PDGFs are important during normal development and in human cancers. In particular, autocrine PDGF signaling has been implicated in various types of malignancies such as gliomas and leukemia. In contrast, paracrine signaling was found in cancers that originate from epithelial cells, where it may be involved in stromal cell recruitment, metastasis, and epithelial-mesenchymal transition. This editorial briefly discusses autocrine and paracrine PDGF signaling and their roles in human cancers, and introduces a series of review articles in this issue that address the possible roles of PDGFs in various processes involved in different types of cancers.
Collapse
Affiliation(s)
- Kun-Wei Liu
- University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
| | | | | |
Collapse
|
92
|
Abstract
Recent collaborative, large-scale genomic profiling of the most common and aggressive brain tumor glioblastoma multiforme (GBM) has significantly advanced our understanding of this disease. The gene encoding platelet-derived growth factor receptor alpha (PDGFRα) was identified as the third of the top 11 amplified genes in clinical GBM specimens. The important roles of PDGFRα signaling during normal brain development also implicate the possible pathologic consequences of PDGFRα over-activation in glioma. Although the initial clinical trials using PDGFR kinase inhibitors have been predominantly disappointing, diagnostic and treatment modalities involving genomic profiling and personalized medicine are expected to improve the therapy targeting PDGFRα signaling. In this review, we discuss the roles of PDGFRα signaling during development of the normal central nervous system (CNS) and in pathologic conditions such as malignant glioma. We further compare various animal models of PDGF-induced gliomagenesis and their potential as a novel platform of pre-clinical drug testing. We then summarize our recent publication and how these findings will likely impact treatments for gliomas driven by PDGFRα overexpression. A better understanding of PDGFRα signaling in glioma and their microenvironment, through the use of human or mouse models, is necessary to design a more effective therapeutic strategy against gliomas harboring the aberrant PDGFRα signaling.
Collapse
Affiliation(s)
- Kun-Wei Liu
- University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA
| | | | | |
Collapse
|
93
|
Li Y, Pal R, Sung LY, Feng H, Miao W, Cheng SY, Tian C, Cheng T. An opposite effect of the CDK inhibitor, p18(INK4c) on embryonic stem cells compared with tumor and adult stem cells. PLoS One 2012; 7:e45212. [PMID: 23049777 PMCID: PMC3458833 DOI: 10.1371/journal.pone.0045212] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2012] [Accepted: 08/14/2012] [Indexed: 12/31/2022] Open
Abstract
Self-renewal is a feature common to both adult and embryonic stem (ES) cells, as well as tumor stem cells (TSCs). The cyclin-dependent kinase inhibitor, p18INK4c, is a known tumor suppressor that can inhibit self-renewal of tumor cells or adult stem cells. Here, we demonstrate an opposite effect of p18 on ES cells in comparison with teratoma cells. Our results unexpectedly showed that overexpression of p18 accelerated the growth of mouse ES cells and embryonic bodies (EB); on the contrary, inhibited the growth of late stage teratoma. Up-regulation of ES cell markers (i.e., Oct4, Nanog, Sox2, and Rex1) were detected in both ES and EB cells, while concomitant down-regulation of various differentiation markers was observed in EB cells. These results demonstrate that p18 has an opposite effect on ES cells as compared with tumor cells and adult stem cells. Mechanistically, expression of CDK4 was significantly increased with overexpression of p18 in ES cells, likely leading to a release of CDK2 from the inhibition by p21 and p27. As a result, self-renewal of ES cells was enhanced. Our current study suggests that targeting p18 in different cell types may yield different outcomes, thereby having implications for therapeutic manipulations of cell cycle machinery in stem cells.
Collapse
Affiliation(s)
- Yanxin Li
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
| | - Rekha Pal
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
| | - Li-Ying Sung
- Institute of Biotechnology, National Taiwan University, Taipei, Taiwan
| | - Haizhong Feng
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
| | - Weimin Miao
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
| | - Shi-Yuan Cheng
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
| | - Cindy Tian
- Center for Regenerative Biology, Department of Animal Science, University of Connecticut, Storrs, Connecticut, United States of America
| | - Tao Cheng
- State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
- Department of Radiation Oncology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States of America
- * E-mail:
| |
Collapse
|
94
|
Song L, Liu L, Wu Z, Li Y, Ying Z, Lin C, Wu J, Hu B, Cheng SY, Li M, Li J. TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. J Clin Invest 2012; 122:3563-78. [PMID: 23006329 DOI: 10.1172/jci62339] [Citation(s) in RCA: 151] [Impact Index Per Article: 12.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2011] [Accepted: 07/26/2012] [Indexed: 01/19/2023] Open
Abstract
The strength and duration of NF-κB signaling are tightly controlled by multiple negative feedback mechanisms. However, in cancer cells, these feedback loops are overridden through unclear mechanisms to sustain oncogenic activation of NF-κB signaling. Previously, we demonstrated that overexpression of miR-30e* directly represses IκBα expression and leads to hyperactivation of NF-κB. Here, we report that miR-182 was overexpressed in a different set of gliomas with relatively lower miR-30e* expression and that miR-182 directly suppressed cylindromatosis (CYLD), an NF-κB negative regulator. This suppression of CYLD promoted ubiquitin conjugation of NF-κB signaling pathway components and induction of an aggressive phenotype of glioma cells both in vitro and in vivo. Furthermore, we found that TGF-β induced miR-182 expression, leading to prolonged NF-κB activation. Importantly, the results of these experiments were consistent with an identified significant correlation between miR-182 levels with TGF-β hyperactivation and activated NF-κB in a cohort of human glioma specimens. These findings uncover a plausible mechanism for sustained NF-κB activation in malignant gliomas and may suggest a new target for clinical intervention in human cancer.
Collapse
Affiliation(s)
- Libing Song
- State Key Laboratory of Oncology in Southern China, Department of Experimental Research, Cancer Center, Zhongshan School of Medicine, Ministry of Education, Sun Yat-sen University, Guangzhou, China
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
95
|
Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, Nishikawa R, Cavenee WK, Cheng SY. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011; 121:4670-84. [PMID: 22080864 DOI: 10.1172/jci58559] [Citation(s) in RCA: 98] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2011] [Accepted: 10/05/2011] [Indexed: 01/06/2023] Open
Abstract
Two hallmarks of glioblastoma multiforme, the most common malignant brain cancer in humans, are aggressive growth and the ability of single glioma cells to disperse throughout the brain. These characteristics render tumors resistant to current therapies and account for the poor prognosis of patients. Although it is known that oncogenic signaling caused by overexpression of genes such as PDGFRA is responsible for robust glioma growth and cell infiltration, the mechanisms underlying glioblastoma malignancy remain largely elusive. Here, we report that PDGFRα signaling in glioblastomas leads to Src-dependent phosphorylation of the guanine nucleotide exchange factor Dock180 at tyrosine 1811 (Dock180(Y1811)) that results in activation of the GTPase Rac1 and subsequent cell growth and invasion. In human glioma cells, knockdown of Dock180 and reversion with an RNAi-resistant Dock180(Y1811F) abrogated, whereas an RNAi-resistant Dock180(WT) rescued, PDGFRα-promoted glioma growth, survival, and invasion. Phosphorylation of Dock180(Y1811) enhanced its association with CrkII and p130(Cas), causing activation of Rac1 and consequent cell motility. Dock180 also associated with PDGFRα to promote cell migration. Finally, phosphorylated Dock180(Y1811) was detected in clinical samples of gliomas and various types of human cancers, and coexpression of phosphorylated Dock180(Y1811), phosphorylated Src(Y418), and PDGFRα was predictive of extremely poor prognosis of patients with gliomas. Taken together, our findings provide insight into PDGFRα-stimulated gliomagenesis and suggest that phosphorylated Dock180(Y1811) contributes to activation of Rac1 in human cancers with PDGFRA amplification.
Collapse
Affiliation(s)
- Haizhong Feng
- Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
96
|
Lefaivre KA, Levy AR, Sobolev B, Cheng SY, Kuramoto L, Guy P. Changes in first hip fracture rates in British Columbia Canada, 1990-2004. Osteoporos Int 2011; 22:2817-27. [PMID: 21305269 DOI: 10.1007/s00198-010-1488-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2010] [Accepted: 11/03/2010] [Indexed: 10/18/2022]
Abstract
UNLABELLED We determined age-standardized first hip fracture rates in British Columbia between 1990 and 2004. We found sex and fracture type rates in keeping with previous reports and that fracture rates have decreased approximately 18% overall in both men and women. INTRODUCTION To determine whether there have been changes in the age-, sex-, and subtype-specific first hip fracture rates in Canadian province of British Columbia (BC) between 1990 and 2004. METHODS Records of all persons aged 60 years and older hospitalized with hip fractures in BC between 1985 and 2004 were obtained from the Canadian Institute for Health Information Discharge Abstract Database. Only the first hip fracture records were included, and fractures likely due to causes other than trauma were excluded. Age- and sex-specific rates were calculated using population denominators from Statistics Canada and direct standardization was used. Age-standardized rates allowed for comparison across years with adjustment for age distribution. RESULTS There were 41,990 records of first hip fracture included, and 73% were in women. Trends in age-specific rates by fracture type were similar to previous reports. Between 1990 and 2004, there has been an age-adjusted 18% decrease in first hip fracture rates in women, and 19% decrease in first hip fracture rates in men. The decrease was statistically significant in femoral neck fractures in women, but not in men. CONCLUSIONS There has been a decrease in age-adjusted hip fracture rates in BC between 1990 and 2004, which is in contrast to previous projections for hip fracture rates in Canada.
Collapse
Affiliation(s)
- K A Lefaivre
- Department of Orthopaedic Surgery, University of British Columbia, 110-828 West 10th Ave, Vancouver, BC, Canada.
| | | | | | | | | | | |
Collapse
|
97
|
Cheng SY, Levy AR, Lefaivre KA, Guy P, Kuramoto L, Sobolev B. Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporos Int 2011; 22:2575-86. [PMID: 21484361 DOI: 10.1007/s00198-011-1596-z] [Citation(s) in RCA: 160] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/01/2010] [Accepted: 02/14/2011] [Indexed: 12/18/2022]
Abstract
UNLABELLED A comprehensive review of literature was conducted to investigate variation in hip fracture incident rates around the world. The original crude incidence rates were standardized for age and sex for comparability. After standardization, the highest rates of hip fracture were found in Scandinavia and the lowest rates in Africa. INTRODUCTION This study was conducted to investigate the geographic trends of the incidence of osteoporotic hip fractures through a comprehensive review of literature. METHODS Studies were identified for inclusion in the review by searching the MEDLINE database via PubMed and applying strict inclusion and exclusion criteria. Age-specific incidence rates were extracted from the articles, and in order to provide a common platform for analysis, we used directly age-standardized and age-sex-standardized rates (using the 2005 United Nations estimates of the world population as standard) to complete the analysis. RESULTS Forty-six full text articles spanning 33 countries/regions were included in the review. For ease of comparison, the results were analyzed by geographic regions: North America, Latin America, Scandinavia, Europe (excluding Scandinavia), Africa, Asia, and Australia. The highest hip fracture rates were found in Scandinavia and the lowest in Africa. We found comparable rates from countries in North America, Australia, and Europe outside of Scandinavia. The diverse makeup of the Asian continent also resulted in quite variable hip fracture rates: ranging from relatively high rates in Iran to low rates, comparable to those from Africa, in mainland China. CONCLUSIONS Given the aging of populations globally, and in the industrialized countries specifically, hip fractures will become a progressively larger public health burden. The geographic trends observed in hip fracture incidence rates can provide important clues to etiology and prevention.
Collapse
Affiliation(s)
- S Y Cheng
- Department of Statistics, University of British Columbia, Vancouver, Canada
| | | | | | | | | | | |
Collapse
|
98
|
Imanishi Y, Hu B, Xiao G, Yao X, Cheng SY. Angiopoietin-2, an angiogenic regulator, promotes initial growth and survival of breast cancer metastases to the lung through the integrin-linked kinase (ILK)-AKT-B cell lymphoma 2 (Bcl-2) pathway. J Biol Chem 2011; 286:29249-29260. [PMID: 21680733 DOI: 10.1074/jbc.m111.235689] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
The early onsets of breast cancer metastasis involve cell retention, survival, and resistant to apoptosis and subsequent growth at target vascular beds and tissues in distant organs. We previously reported that angiopoietin-2 (Ang2), an angiogenic regulator stimulates MCF-7 breast tumor metastasis from their orthotopic sites to distant organs through the α(5)β(1) integrin/integrin-linked kinase (ILK)/Akt pathway. Here, by using an experimental tumor metastasis model and in vitro studies, we further dissect the underlying mechanism by which Ang2 promotes the initial growth and survival of MCF-7 breast cancer metastasis in the lung of animals. We show that Ang2 increases cell survival and suppresses cell apoptosis through ILK-induced phosphorylation of Akt1, Akt2, and up-regulation of Bcl-2 in breast cancer cells. Inhibition of ILK, Akt1, and Akt2, and their effector Bcl-2 diminishes Ang2-stimulated breast cancer cell survival and Ang2-attenuated apoptosis in vitro, and initial survival and growth of breast cancer metastasis in the lung of animals. Additionally, siRNA knockdown of endogenous Ang2 in three human metastatic breast cancer cell lines also inhibits phosphorylation of Akt, expression of Bcl-2, and tumor cell survival, migration, and increases cell apoptosis. Since increased expression of Ang2 correlates with elevated potential of human breast cancer metastasis in clinic, our data underscore the importance that up-regulated Ang2 not only stimulates breast cancer growth and metastasis at late stages of the process, but is also critical at the initiating stages of metastases onset, thereby suggesting Ang2 as a promising therapeutic target for treating patients with metastatic breast cancer.
Collapse
Affiliation(s)
- Yorihisa Imanishi
- Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Department of Otorhinolaryngology, Head and Neck Surgery, Keio University, School of Medicine, Shinjuku, Tokyo 160-8582, Japan
| | - Bo Hu
- Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213.
| | - Gutian Xiao
- Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Department of Microbiology & Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213
| | - Xuebiao Yao
- Anhui Laboratory of Cellular Dynamics and Chemical Biology, Hefei National Laboratory for Physical Sciences at Nanoscale, Hefei 230027, China, and; Department of Physiology, Morehouse School of Medicine, Atlanta, Georgia 30310
| | - Shi-Yuan Cheng
- Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213.
| |
Collapse
|
99
|
Liu KW, Feng H, Bachoo R, Kazlauskas A, Smith EM, Symes K, Hamilton RL, Nagane M, Nishikawa R, Hu B, Cheng SY. SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans. J Clin Invest 2011; 121:905-17. [PMID: 21393858 DOI: 10.1172/jci43690] [Citation(s) in RCA: 67] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2010] [Accepted: 12/22/2010] [Indexed: 01/01/2023] Open
Abstract
Recent collaborative efforts have subclassified malignant glioblastomas into 4 clinical relevant subtypes based on their signature genetic lesions. Platelet-derived growth factor receptor α (PDGFRA) overexpression is concomitant with a loss of cyclin-dependent kinase inhibitor 2A (CDKN2A) locus (encoding P16INK4A and P14ARF) in a large number of tumors within one subtype of glioblastomas. Here we report that activation of PDGFRα conferred tumorigenicity to Ink4a/Arf-deficient mouse astrocytes and human glioma cells in the brain. Restoration of p16INK4a but not p19ARF suppressed PDGFRα-promoted glioma formation. Mechanistically, abrogation of signaling modules in PDGFRα that lost capacity to bind to SHP-2 or PI3K significantly diminished PDGFRα-promoted tumorigenesis. Furthermore, inhibition of SHP-2 by shRNAs or pharmacological inhibitors disrupted the interaction of PI3K with PDGFRα, suppressed downstream AKT/mTOR activation, and impaired tumorigenesis of Ink4a/Arf-null cells, whereas expression of an activated PI3K mutant rescued the effect of SHP-2 inhibition on tumorigenicity. PDGFRα and PDGF-A are coexpressed in clinical glioblastoma specimens, and such co-expression is linked with activation of SHP-2/AKT/mTOR signaling. Together, our data suggest that in glioblastomas with Ink4a/Arf deficiency, overexpressed PDGFRα promotes tumorigenesis through the PI3K/AKT/mTOR-mediated pathway regulated by SHP-2 activity. These findings functionally validate the genomic analysis of glioblastomas and identify SHP-2 as a potential target for treatment of glioblastomas.
Collapse
Affiliation(s)
- Kun-Wei Liu
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15213, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X, Liao J, Ward T, Xia P, Emenari C, Ding X, Thompson W, Ma K, Zhu J, Aikhionbare F, Dou K, Cheng SY, Yao X. Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res 2011; 71:1721-9. [PMID: 21363921 DOI: 10.1158/0008-5472.can-09-4683] [Citation(s) in RCA: 62] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
During progression of hepatocellular carcinoma, multiple genetic and epigenetic alterations act to posttranslationally modulate the function of proteins that promote cancer invasion and metastasis. To define such abnormalities that contribute to liver cancer metastasis, we carried out a proteomic comparison of primary hepatocellular carcinoma and samples of intravascular thrombi from the same patient. Mass spectrometric analyses of the liver cancer samples revealed a series of acidic phospho-isotypes associated with the intravascular thrombi samples. In particular, we found that Thr567 hyperphosphorylation of the cytoskeletal protein ezrin was tightly correlated to an invasive phenotype of clinical hepatocellular carcinomas and to poor outcomes in tumor xenograft assays. Using phospho-mimicking mutants, we showed that ezrin phosphorylation at Thr567 promoted in vitro invasion by hepatocarcinoma cells. Phospho-mimicking mutant ezrinT567D, but not the nonphosphorylatable mutant ezrinT567A, stimulated formation of membrane ruffles, suggesting that Thr567 phosphorylation promotes cytoskeletal-membrane remodeling. Importantly, inhibition of Rho kinase, either by Y27632 or RNA interference, resulted in inhibition of Thr567 phosphorylation and a blockade to cell invasion, implicating Rho kinase-ezrin signaling in hepatocellular carcinoma cell invasion. Our findings suggest a strategy to reduce liver tumor metastasis by blocking Rho kinase-mediated phosphorylation of ezrin.
Collapse
Affiliation(s)
- Yong Chen
- Department of Hepatobiliary Surgery, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shanxi, P.R. China
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|